Development and validation of a dissolution test for primaquine/polyethylene oxide matrix tablets

AUTOR(ES)

Cruz, Ariane P., Bertol, Charise D., Murakami, Fábio S., Pereira, Rafael N., Valente, Bruno R., Silva, Marcos A. S., Koester, Letícia S.

FONTE

Quím. Nova

DATA DE PUBLICAÇÃO

2013

RESUMO

A simple, precise, specific, repeatable and discriminating dissolution test for primaquine (PQ) matrix tablets was developed and validated according to ICH and FDA guidelines. Two UV assaying methods were validated for determination of PQ released in 0.1 M hydrochloric acid and water media. Both methods were linear (R²>0.999), precise (R.S.D.<1.87%) and accurate (97.65-99.97%). Dissolution efficiency (69-88%) and equivalence of formulations (f2) was assessed in different media and apparatuses (basket/100 rpm and paddle/50 rpm) tested. Discriminating condition was 900 mL aqueous medium, basket at 100 rpm and sampling times at 1, 4 and 8 h. Repeatability (R.S.D.<2.71%) and intermediate precision (R.S.D.<2.06%) of dissolution method were satisfactory.

Documentos Relacionados

• Development and validation of a dissolution test for telithromycin in coated tablets
• Development and validation of dissolution method for carvedilol compression-coated tablets
• Dissolution test for glibenclamide tablets
• Development and validation of a dissolution test for diltiazem hydrochloride in immediate release capsules
• Development of new dissolution test and HPLC-RP method for anti-parasitic ornidazole coated tablets